Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02951988 · ClinicalTrials.gov registry record · Phase 3
A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder
A Phase 3 study, sponsored by Naurex, Inc, an affiliate of Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,304
- Enrollment target
NCT02951988: Completed Phase 3 study, sponsored by Naurex, Inc, an affiliate of Allergan.
NCT02951988 is a Phase 3 study that has completed, run by Naurex, Inc, an affiliate of Allergan. The registered enrollment target is 1,304 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02951988, a Phase 3 study, has completed, sponsored by Naurex, Inc, an affiliate of Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,304 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety and tolerability of rapastinel 450 milligrams (mg) intravenous (IV) once weekly or once every 2 weeks versus placebo as an adjunctive treatment to ongoing anti-depressive therapy (ADT) in the prevention of relapse in participants with Major Depressive Disorder (MDD).
Primary Outcome
The time in days to first relapse is defined as the number of days from the date of randomization to the first relapse.
Interventions
- DRUG Rapastinel
- DRUG Placebo-matching Rapastinel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,304 participants |
| Start Date | 2016-11-13 |
| Est. Completion | 2019-02-22 |
| Phase | Phase 3 |
What the finished NCT02951988 record still lists
NCT02951988 is an interventional study that assigns participants to a tested intervention. Its 1,304 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% higher).
The record links to 0 conditions, and to 2 interventions - of which Rapastinel is the first listed.
NCT02951988 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02951988 about?
NCT02951988 is a clinical study titled "A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder". This study will evaluate the efficacy, safety and tolerability of rapastinel 450 milligrams (mg) intravenous (IV) once weekly or once every 2 weeks versus placebo as an adjunctive treatment to ongoing anti-depressive therapy (ADT) in the prevention of relapse in participants with Major Depressive Di...
What is the current status of trial NCT02951988?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,304 participants. The study started on 2016-11-13. Estimated completion is 2019-02-22.
What interventions are being tested in trial NCT02951988?
The interventions under investigation include: Rapastinel (DRUG), Placebo-matching Rapastinel (DRUG).
Who is sponsoring clinical trial NCT02951988?
This trial is sponsored by Naurex, Inc, an affiliate of Allergan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02951988's enrollment target sits among peer trials
1,304 188th of 2000 higher than 1,813 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04171323 · 1,305 participants · NA
The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia
- NCT06517901 · 1,306 participants · NA
Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer
- NCT04474223 · 1,300 participants · Phase 3
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
- NCT04792684 · 1,300 participants
Collection of Samples USOPTIVAL Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI